Companies to lead digital transformation of pathology and cancer diagnosis
NEW YORK–(BUSINESS WIRE)–Paige announced a collaboration with Microsoft to apply the power of artificial intelligence (AI) to digital pathology images to develop and deliver a new generation of clinical applications and computational biomarkers to transform cancer diagnosis and patient care. Microsoft will also make a strategic investment in Paige to accelerate the development and deployment of life-saving AI diagnostics.
Through the collaboration, Paige and Microsoft will scale Paige’s technology globally and accelerate the adoption of AI in digital pathology.
Paige will use Microsoft Azure as its cloud provider for the Paige Platform, a comprehensive solution to power a lab’s digital pathology workflow that consists of data management, cloud storage options and FullFocus®, an FDA-cleared whole-slide image viewer. As part of this collaboration, Paige will become a Microsoft Cloud for Healthcare partner and enable Microsoft to enhance its own offerings for healthcare customers.
Clinical AI applications have the potential to help pathologists diagnose cancer more confidently and efficiently, with the ultimate goal of improving patient care. Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications, is currently the only company to have received FDA approval for an AI algorithm in pathology. Paige puts the power of AI into the hands of pathologists by developing novel AI applications on a powerful platform, making it easy to deploy AI in laboratories globally.
Paige will work with other entities, including Microsoft Research on developing large scale machine learning models to push the boundaries of research in oncology and pathology. Paige is also working with Nuance, a Microsoft company, on integrating their offering with Nuance’s Precision Imaging Network.
“We are thrilled to partner with Microsoft to make AI cancer diagnostics accessible to countless laboratories and hospitals around the world as part of the digital transformation of pathology,” said Andy Moye, Ph.D., Chief Executive Officer at Paige. “We believe that Microsoft’s world-class AI resources, cloud infrastructure, global reach and scale, combined with our deep expertise in developing AI cancer diagnostics, will drive a new era of diagnostics and precision treatment to improve the lives of patients.”
“The application of technology to help clinicians and researchers further enhance patient care and, in many cases, provide life-saving treatment is a core tenet for Microsoft in health and life sciences,” said Tom McGuinness, corporate vice president, Global Healthcare & Life Sciences, Microsoft. “We look forward to further collaborating with Paige and giving Microsoft Cloud for Healthcare customers the ability to harness the power and promise of AI in digital pathology.”
Paige technology will be offered as a partner solution in Microsoft Cloud for Healthcare, expanding access to cutting-edge digital cancer diagnostic tools. Microsoft Cloud for Healthcare connects customers with trusted partner solutions that make it easier to create personalized patient experiences, give clinicians connected tools, and adopt data standards important to healthcare. Together with Nuance, healthcare organizations can access the broadest and deepest set of trusted AI solutions to address the biggest challenges in the industry. Paige becoming a Microsoft Cloud for Healthcare partner extends the solution’s robust capabilities and helps Paige reach new customers.
Paige is using the power of AI to drive a new era of cancer discovery and treatment. To improve the lives of patients with cancer, Paige has created a cloud-based platform that transforms pathologists’ workflow and increases diagnostic confidence as well as productivity, all on a global scale. Paige is the first company to receive FDA approval for a clinical AI application in digital pathology. The same Paige technology empowers pharmaceutical companies to more effectively evaluate treatment options for patients and design new biomarkers for drug development so that every patient gets precise treatment options.
Paige Media Relations: